Carlson Capital L P Galapagos Nv Transaction History

Carlson Capital L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$37.4 - $44.52 $561,000 - $667,800	-15,000 Reduced 37.5%	25,000 $1.02 Million
Q1 2023 May 12, 2023	BUY	$36.5 - $48.0 $182,500 - $240,000	5,000 Added 14.29%	40,000 $1.55 Million
Q4 2022 Feb 14, 2023	SELL	$37.44 - $46.51 $374,400 - $465,100	-10,000 Reduced 22.22%	35,000 $1.55 Million
Q3 2022 Nov 14, 2022	BUY	$42.27 - $57.6 $422,700 - $576,000	10,000 Added 28.57%	45,000 $1.92 Million
Q1 2022 May 13, 2022	SELL	$51.32 - $68.5 $256,600 - $342,500	-5,000 Reduced 12.5%	35,000 $2.17 Million
Q4 2021 Feb 11, 2022	BUY	$47.03 - $57.12 $1.88 Million - $2.28 Million	40,000 New	40,000 $2.21 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Carlson Capital L P, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital L P with notifications on news.